Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: PM.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Philip Morris (PM) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$191

+1.3%+4.6% incl. dividends

2031

5-Year

NEUTRAL

$232

+23.1%+44.1% incl. dividends

Published batch insight

Smoke Free Margin Expansion Clashes With Multiple Compression Against High Yields

High consensus confirms rapid smoke-free product volume compounding and unmatched combustible pricing power will drive high-single-digit operating profit expansion. However, sharp valuation divergence centers on equity multiple contraction against five-percent benchmark bond yields, bounding five-year equity appreciation to earnings compounding alongside reliable dividends.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Michael Burry (Vulture), Superintelligence (Anthropologist), J.P. Morgan (Titan), Elon Musk (Visionary), Warren Buffett (Value Purist), Universal Investor (Polymath), Ray Dalio (Strategist), Machiavelli (Insider), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Philip Morris at the forecast anchor (2026-09-18): $14,405 in five years versus $13,892 for S&P 500 benchmark.

Philip Morris · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 3.2% net dividend yield for Philip Morris.

Figure: Five-year synthesized consensus value path for Philip Morris compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 188.62 USD1-year price return: +1.31%5-year price return: +23.06%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	187.02	-0.85%	-0.85%	Elevated Treasury yields near 5.0% and post-rate-hike monetary tightness compress defensive valuation multiples. This macro friction absorbs the recent 8.8% dividend increase and robust ZYN shipments, leaving equity pricing essentially flat.
Q1 2027	186.65	-0.20%	-1.05%	Seasonal post-holiday combustible volume weakness and foreign exchange headwinds create temporary profit drag. Broader multiple normalization across consumer staples pulls equity values lower despite management reaffirming high-single-digit organic constant-currency earnings guidance.
Q2 2027	188.96	+1.24%	+0.18%	First-quarter earnings demonstrate accelerating international heated tobacco conversion across Europe and Japan. Smoke-free gross margin expansion and resilient emerging-market combustible price realization stabilize market sentiment, enabling a modest equity rebound.
Q3 2027	191.10	+1.13%	+1.31%	Retail volume velocity accelerates ahead of the annual dividend announcement. FDA modified-risk marketing authorizations for modern oral pouches expand adult consumer conversion, driving positive earnings revisions that overcome persistent bond-yield competition.
Q4 2027	193.34	+1.17%	+2.50%	Commercial production ramps at domestic manufacturing facilities, debottlenecking retail pouch fulfillment. Robust operating cash collections and smoke-free sales approaching 45% of group turnover generate modest capital appreciation into year-end.
Q1 2028	195.55	+1.14%	+3.67%	State-level modern oral excise tax discussions and corporate bond refinancing at higher prevailing coupons introduce minor margin hesitation. Stable international cigarette pricing offsets regulatory drag, leaving quarterly equity performance balanced.
Q2 2028	198.71	+1.62%	+5.35%	Commissioning of automated production lines lowers unit manufacturing costs, widening consolidated gross margins. Heated tobacco consumable adoption across secondary European metropolitan markets drives operating profit expansion above sell-side consensus.
Q3 2028	200.59	+0.94%	+6.34%	Management delivers another high-single-digit dividend hike supported by expanding free cash conversion. Ongoing balance-sheet deleveraging toward target ratios attracts defensive institutional asset allocators, supporting steady quarterly price appreciation.
Q4 2028	202.63	+1.02%	+7.43%	Smoke-free net revenues approach fifty percent of consolidated sales, reinforcing corporate transformation milestones. Reliable holiday cash generation and disciplined combustible pricing power defend equity valuation against broader macroeconomic deceleration.
Q1 2029	205.10	+1.22%	+8.74%	Annual combustible pricing resets take effect across Latin America and Asia, compensating for volume attrition. Operating cash flow easily covers debt obligations, producing fractional equity gains amid a stable rate environment.
Q2 2029	209.01	+1.90%	+10.81%	International oral nicotine rollout into emerging consumer markets gains measurable traction. Superior consumable unit economics and factory automation efficiencies expand operating income, prompting constructive institutional equity accumulation.
Q3 2029	211.14	+1.02%	+11.94%	Predictable annual dividend compounding and free cash flow conversion exceeding 85% of operating profit reinforce defensive positioning. Steady consumer retention across smoke-free platforms drives moderate, low-volatility share price appreciation.
Q4 2029	213.11	+0.93%	+12.98%	Selective European excise duty adjustments on modern nicotine formulations create transient sentiment friction. Strong year-end free cash flow and disciplined SG&A containment preserve profitability, keeping share performance flat to slightly positive.
Q1 2030	216.01	+1.36%	+14.52%	Audited disclosures confirm smoke-free products generate over 52% of net revenues. Structural mix shift toward high-margin consumables cushions reported earnings against late-cycle economic cooling, supporting dependable equity compounding.
Q2 2030	219.14	+1.45%	+16.18%	Expanding commercial adoption of next-generation heated tobacco hardware stimulates recurring consumable stick replenishment. Improved manufacturing scale efficiencies across global supply chains widen operating margins, lifting quarterly financial results.
Q3 2030	221.33	+1.00%	+17.34%	Deleveraging milestones lower net debt ratios, unlocking balance-sheet flexibility for selective share repurchases alongside the regular dividend increase. Favorable capital return announcements provide a durable valuation floor.
Q4 2030	222.76	+0.65%	+18.10%	Valuation multiples settle near historical staples medians of nineteen times earnings as interest rates stabilize. High-margin oral and heated product lines generate resilient cash flows, preserving price stability into calendar close.
Q1 2031	225.82	+1.37%	+19.72%	Core international cigarette pricing power delivers reliable mid-single-digit profit gains, offsetting structural volume erosion. Sustained brand equity in premium nicotine categories ensures uninterrupted operational cash flow generation.
Q2 2031	229.41	+1.59%	+21.63%	Smoke-free product volume dominance approaches sixty percent of group totals, reducing regulatory discount overhangs. Strong cash returns and low capital expenditure requirements drive steady quarterly equity price gains.
Q3 2031	232.12	+1.18%	+23.06%	The five-year transformation forecast closes with the company operating as a mature smoke-free cash generator. Compounded earnings growth and reliable dividend reinvestment deliver solid cumulative total returns across normalized valuation multiples.

The central investment thesis resolves a structural paradox: stellar operational execution across smoke-free platforms versus severe multiple compression in a restrictive interest-rate regime. Smoke-free offerings, headlined by IQOS heated tobacco and ZYN modern oral pouches, now represent over 42% of net revenue, structurally elevating gross margins above 67%. Addictive consumer demand guarantees inelastic combustible pricing realizations of 6% to 8%, which systematically offset 2% to 4% secular cigarette volume attrition and fund high-single-digit adjusted EPS growth. However, equity duration acts as a powerful brake. Trading at roughly 22x forward and 27x trailing earnings, the equity offers an earnings yield barely competitive with 5.0% risk-free Treasuries, leaving zero margin of safety. Debt refinancing across $49 billion in liabilities with negative accounting equity further limits aggressive buybacks. Cumulative five-year equity returns will therefore be bounded by steady operating earnings compounding, tempered by multiple mean-reversion toward 18x to 20x historical staple norms.

Key insights

Operating leverage from domestic manufacturing debottlenecking expands gross margins, but intensified modern oral promotional allowances will cap incremental margin conversion.
Premium consumer staples dividend yields struggle to command historical valuation premiums when risk-free sovereign debt anchors at five percent.
Negative accounting equity represents historical buyback capitalization rather than insolvency, yet refinancing escalating debt maturities diverts cash from share repurchases.

Deep Dive

Consensus market narrative treats the enterprise as an unassailable consumer-technology compounder deserving a premium multiple. Investors anchor on explosive ZYN pouch adoption in the United States and FDA modified-risk marketing authorizations, pricing in uninterrupted double-digit smoke-free expansion. The crowd assumes high consumer pricing power effortlessly neutralizes secular combustible volume declines, while systematically ignoring multiple vulnerability against 5.0% benchmark Treasury yields and elevated debt-servicing burdens.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd overestimates value by pricing the equity at 22x to 27x earnings in a restrictive monetary regime, leaving zero margin of safety. While the market correctly recognizes operational excellence in smoke-free conversion, its blind spot is equity duration: a 3.4% dividend yield faces asset-allocation headwinds when risk-free Treasuries yield 5.0%. Furthermore, consensus overlooks accelerating promotional discounting in modern oral nicotine and refinancing drag across $49 billion in debt, meaning multiple compression will substantially absorb underlying operating profit compounding.

Repricing catalyst

Successive quarterly earnings reports through 2027 will enforce valuation multiple rationalization. Decelerating United States modern oral shipment growth alongside rising retail promotional allowances will demonstrate that category expansion requires heavy commercial reinvestment. Once investors recognize that smoke-free gross margin gains cannot fully neutralize multiple mean-reversion toward 18x to 20x historical norms, institutional capital will re-rate the stock as a dependable income compounder rather than a premium growth platform.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive central bank policy, with benchmark Treasury yields near 5.0%, constitutes a definitive valuation headwind. While addictive, price-inelastic products insulate consumer demand from inflation and allow reliable pass-through pricing, elevated sovereign yields directly penalize low-yielding consumer staples multiples. Additionally, higher borrowing costs steadily escalate debt-refinancing expenses across the company's leveraged capital structure.

Published consensus context

Advisor disagreement

The primary analytical disagreement concerns whether Philip Morris merits a premium consumer-growth multiple or will inevitably derate toward traditional tobacco valuations. Bullish views argue that crossing 50% smoke-free revenue, combined with FDA modified-risk designations, justifies multiples above 22x earnings. Conversely, value and credit-focused perspectives maintain that competing against 5.0% risk-free Treasury yields with negative book equity and $49 billion in debt makes multiple contraction toward 18x mathematically inevitable. Resolving this tension requires tracking whether American modern oral gross profit margins re-expand as newly commissioned manufacturing scales, or continue to erode under competitive promotional discounting.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Smoke-free margin mix structural accretion: Smoke-free offerings generate over 42% of consolidated net revenues and command gross margins structurally superior to traditional cigarettes. As heated tobacco consumables and modern oral pouches approach half of total group volume by 2028, favorable mix shift widens consolidated gross margins above 67%, driving persistent operating income expansion despite combustible volume attrition. Expected impact: +22%.
Modern oral nicotine domestic manufacturing ramp: Commercial scaling of the $1.2 billion automated manufacturing campus in Aurora, Colorado debottlenecks retail pouch supply shortages across North America. Domestic production eliminates expensive air-freight logistics, lowers unit cost of goods sold, and fulfills double-digit retail offtake demand, expanding Swedish Match operating margins and boosting recurring free cash conversion. Expected impact: +18%.
Combustible pricing power and inelasticity: Neurochemical demand inelasticity and dominant international brand equity allow routine 6% to 8% combustible price realizations, consistently outstripping secular 2% to 4% volume declines. This traditional tobacco cash engine generates over $10 billion in baseline annual operating income, self-funding smoke-free infrastructure investments and underwriting progressive dividend increases without dilutive external equity. Expected impact: +14%.
FDA modified risk regulatory rampart: FDA authorizations granting Modified Risk Tobacco Product claims for twenty oral nicotine pouch variants establish a formidable scientific and legal barrier to entry. Subscale synthetic and generic competitors cannot easily fund the multi-million-dollar toxicological dossiers required for compliance, legally protecting shelf space, retail price realization, and market share across premier convenience channels. Expected impact: +11%.

Top frictions and headwinds

Valuation multiple compression against yields: Trading between 22x and 27x earnings against a 5.0% 10-year Treasury yield compresses the equity risk premium. In a restrictive monetary environment, a 3.4% dividend yield faces severe asset allocation competition from risk-free cash and bonds, exerting persistent downward gravity toward historical consumer staple valuation multiples of 18x to 20x. Expected impact: -20%.
Modern oral promotional pricing warfare: Aggressive retail discounting and multi-can promotional allowances from rival brands like Velo and on! are actively challenging modern oral category pricing integrity. To defend convenience store shelf space, increased promotional allowances and trade marketing expenditures compress pouch operating margins, dampening net revenue realization despite expanding consumer shipment volumes. Expected impact: -9%.
Fiscal excise tax equalization creep: Indebted sovereign governments confronting fiscal deficits are aggressively targeting heated tobacco and modern oral nicotine to close the excise tax differential with combustible cigarettes. Equalizing excise duties narrows the retail price advantage of reduced-risk alternatives, forcing manufacturer margin absorption and creating friction against consumer conversion velocity. Expected impact: -8%.
Leveraged balance sheet refinancing drag: Carrying approximately $49 billion in funded debt and negative accounting equity following the Swedish Match transaction exposes cash flows to higher borrowing costs. Refinancing maturing debt at prevailing interest rates increases annual interest expense, absorbing operating cash flow and delaying discretionary share buybacks in favor of mandatory debt service. Expected impact: -7%.

Tail risks

Federal modern oral flavor prohibition: Coordinated federal or state regulatory intervention enacting sweeping bans on non-tobacco pouch flavors would severely impair consumer adoption by 2028. Because mint and fruit variants represent over 70% of pouch consumption, a comprehensive prohibition would trigger catastrophic volume contraction, stranding domestic manufacturing capacity and destroying operating profit. Probability: +28%. Expected impact: -25%.
Punitive European heated tobacco tax harmonization: An overhauled European Union Tobacco Taxation Directive mandating immediate excise duty parity between heated tobacco consumables and combustible cigarettes by 2028 would eliminate the category's consumer savings incentive. Removing the preferential tax gap would compress unit gross margins toward 60% and derail European smoke-free conversion momentum. Probability: +32%. Expected impact: -19%.

Tail opportunities

Expedited United States heated tobacco breakthrough: Rapid FDA premarket and modified-risk authorizations for the IQOS ILUMA induction platform would enable nationwide retail distribution across the lucrative American market by 2028. Capturing 5% of domestic combustible cigarette volume would unlock over $3 billion in high-margin revenue, driving double-digit operating income growth and triggering multiple re-expansion. Probability: +34%. Expected impact: +22%.
European modern oral category deregulation: A coordinated European Union regulatory reform lifting restrictions on tobacco-free nicotine pouches across key Western European member states by late 2028 would unlock a massive consumer demographic. Deploying Swedish Match infrastructure across Germany and France would rapidly expand international smoke-free volumes and drive significant upward cash-flow revisions. Probability: +26%. Expected impact: +17%.

What to monitor

Thesis watchpoints

-- Smoke-free revenue exceeding 46% of consolidated sales with stabilizing United States pouch gross margins confirms sustained operating leverage through 2027.

Key insights

United States modern oral retail value share falling below 55% under aggressive competitor discounting signals category saturation and margin deterioration through 2028.
Consolidated net debt-to-EBITDA failing to decline below 2.0x while benchmark Treasury yields remain above 4.75% mandates full multiple reassessment.

Company Financial Analysis

Philip Morris Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Top-line revenue shows powerful momentum, reaching $42.5 billion over the trailing twelve months, propelled by double-digit volume expansion in smoke-free products. Heated tobacco and modern oral pouches now generate over 42% of total company sales, successfully replacing shrinking cigarette volumes. While headline accounting profits experienced temporary swings due to a $511 million non-cash investment impairment in Canada, adjusted operating income reached a robust $16.06 billion, reflecting genuine underlying business health. Free cash flow generation remained outstanding at $12.72 billion, easily funding the board's recent 8.8% dividend increase. However, growth is becoming regionally uneven. International operations continue delivering strong profit growth, while domestic oral nicotine faces heavy promotional discounting that temporarily dampens profit conversion.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 40.6B	USD 11.3B	USD 10.7B
2024	USD 37.9B	USD 7B	USD 10.8B
2023	USD 35.2B	USD 7.8B	USD 7.9B
2022	USD 31.8B	USD 9B	USD 9.7B
2021	USD 31.4B	USD 2.2B	USD 11.2B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	22.0x	TTM	Native	USD / USD
2024	26.5x	TTM	Native	USD / USD
2023	18.7x	TTM	Native	USD / USD
2022	17.4x	Annual	Native	USD / USD
2021	66.4x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability margins have expanded structurally, with gross margin widening to 67.1% and operating margin reaching 36.7%. This expansion is powered by an advantageous product mix, because heated tobacco units and oral nicotine pouches command substantially higher profit margins than conventional cigarettes. Furthermore, steady 6% to 8% price increases on traditional cigarettes reliably outpace inflation. Looking ahead, profit margin expansion will encounter natural friction. To defend market leadership against aggressive competitor discounting in convenience stores, the company has increased promotional spending on oral pouches. While overall margins remain well protected by manufacturing scale, explosive margin surprises will be harder to achieve.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 14.9B	36.7%	27.9%
2024	USD 13.4B	35.4%	18.6%
2023	USD 11.6B	32.9%	22.1%
2022	USD 12.2B	38.6%	28.5%
2021	USD 2.9B	9.4%	7.1%

Balance sheet and leverage

AI Review

The balance sheet reflects substantial financial leverage, closing with $49.1 billion in total debt and negative accounting equity of $9.99 billion. Negative book net worth is not a sign of financial distress; it is the predictable accounting result of decades of share repurchases and the debt-funded acquisition of Swedish Match. Operating cash flow covers annual interest obligations by a comfortable ten times. Nevertheless, carrying significant debt into a higher interest-rate environment requires strict capital discipline. As older, low-interest bonds mature, refinancing them at higher rates increases annual interest costs. Consequently, management must prioritize steady debt reduction toward a 2.0x leverage target, leaving little room for discretionary share repurchases.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 48.8B	USD 4.9B	USD 44B net debt	0.96x
2024	USD 45.7B	USD 4.2B	USD 41.5B net debt	0.88x
2023	USD 47.9B	USD 3.1B	USD 44.8B net debt	0.75x
2022	USD 43.1B	USD 3.2B	USD 39.9B net debt	0.72x
2021	USD 25B	USD 4.5B	USD 1.5B net cash	4.73x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains disciplined capital spending, directing roughly 3.9% of annual revenue, or approximately $1.6 billion, into strategic manufacturing infrastructure. The primary capital commitment is a $1.2 billion manufacturing campus in Aurora, Colorado, built to eliminate retail shortages for oral nicotine pouches. Reinvestment in legacy cigarette factories has been curtailed to focus capital where customer demand is growing. This capital-light manufacturing model delivers rapid economic paybacks. Once automated pouch and heated consumable production lines reach full design speed, unit manufacturing costs drop sharply. This high-efficiency infrastructure generates formidable competitive barriers that smaller rivals cannot easily match, protecting future free cash flow.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 1.6B	--
2024	USD 1.4B	USD 759M
2023	USD 1.3B	USD 709M
2022	USD 1.1B	USD 642M
2021	USD 748M	USD 617M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	6	+4.2%	Not available	ORIGINAL
5Y	NEUTRAL	91	+43.2%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	181.08	187.27	194.28	14
+6M	March 18, 2027	175.64	186.22	198.16	14
+9M	June 18, 2027	177.4	188.37	204.11	14
+1Y	September 18, 2027	173.85	190.43	208.19	14
+15M	December 18, 2027	177.33	192.61	212.36	14
+18M	March 18, 2028	172.01	194.32	214.48	14
+21M	June 18, 2028	177.17	197.66	220.91	14
+2Y	September 18, 2028	175.4	199.66	225.33	14
+27M	December 18, 2028	178.91	201.79	229.84	14
+30M	March 18, 2029	175.33	203.87	232.14	14
+33M	June 18, 2029	177.08	207.7	239.1	14
+3Y	September 18, 2029	180.62	210.22	243.88	14
+39M	December 18, 2029	178.82	211.93	248.76	14
+42M	March 18, 2030	180.6	214.66	251.25	14
+45M	June 18, 2030	184.22	217.89	256.27	14
+4Y	September 18, 2030	182.37	220.13	261.4	14
+51M	December 18, 2030	186.02	221.7	266.63	14
+54M	March 18, 2031	187.88	224.58	269.29	14
+57M	June 18, 2031	187.88	228.05	274.68	14
+5Y	September 18, 2031	189.76	230.68	280.17	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus reveals a structural transformation where high-margin smoke-free products contribute over 42% of revenue, propelled by heated tobacco and oral nicotine pouches. Inelastic combustible pricing consistently offsets 2% to 4% secular cigarette volume attrition, generating over $12 billion in annual free cash flow that funds progressive dividend expansion. However, reports heavily correlate on valuation multiple compression as the primary friction: trading at 22x to 27x earnings against a 5.0% Treasury yield compresses the equity risk premium. The strongest contrarian perspective, modeling multiple re-expansion toward 24x on an imminent American heated-tobacco rollout, is downweighted because protracted regulatory reviews and rising promotional competition curb multiple expansion. Heavy weight is awarded to analyses verifying primary SEC filings, highlighting that H1 2026 net income volatility stemmed from non-cash equity impairments rather than operational decay. Modest weights are assigned to viewpoints projecting severe multiple collapse or unverified pharmaceutical demand destruction.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.4/100

Exceptional evidentiary quality synthesizing primary SEC filings, Barclays conference updates, and the September 2026 dividend raise. Causal analysis reconciling currency-neutral EPS growth against American oral gross margin contraction provides the most realistic fundamental anchor.

AI RESEARCHER

Universal Investor AI

The Polymath

The Anthropologist

Gemini 3.8 Flash

Weight2.9/100

Offers compelling arguments regarding biological consumer addiction moats and debt refinancing friction. However, its path models extreme equity stagnation that underweights secular international heated tobacco compounding and proven pricing power.

Skip to references

Research Provenance

References & Context

This Philip Morris consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 97 deduplicated sources retained for this batch.

And 82 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.